SIM Acquisition Corp. I Business Summary

SIM Acquisition Corp. I (SIMA) is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands, structured as a "blank check" entity to facilitate a merger, asset acquisition, or similar business combination. As a pre-revenue shell company, SIMA does not currently generate operational income; its revenue model is entirely dependent on the post-combination performance of its eventual acquisition target. The company primarily targets high-growth, private enterprises within the healthcare sector, leveraging its team's expertise in intellectual property and clinical innovation to identify undervalued assets. In the competitive SPAC market, SIMA operates alongside peers such as Graf Global Corp. (GRAF), Cantor Equity Partners I (CEPO), and Drugs Made In America Acquisition (DMAA), positioning itself as a specialized vehicle focused on healthcare-specific regulatory and operational arbitrage. The company's leadership underwent a significant transition in January 2026, with Christopher Devall appointed as Chief Executive Officer following a change in sponsor control. Devall brings a robust operational pedigree, having previously served as Chief Operating Officer of Dominari Holdings, Inc. and in senior roles within the U.S. Department of Defense, supported by an MBA from the University of Virginia’s Darden School of Business. He is joined by David Kutcher, who remains the Chief Financial Officer and Director, providing essential financial continuity and strategic oversight. The company is backed by SIM Sponsor 1 LLC, which recently saw a full membership interest acquisition by a group of accredited investors, and maintains a strategic relationship with Cantor Fitzgerald, which serves as the primary underwriter and financial advisor for the firm’s initial business combination.